靶向与免疫治疗在成人TP53突变急性淋巴细胞白血病中的疗效
该研究回顾性评估了47例接受布林妥莫单抗、奥英妥珠单抗和/或CD19 CAR T细胞治疗的成人TP53突变急性淋巴细胞白血病患者,三种治疗均诱导较高MRD阴性完全缓解率,但缓解持续时间短,获得缓解后行异基因造血干细胞移植可改善12个月无白血病生存,布林妥莫单抗后复发常表现为CD19阴性。
要点
- 布林妥莫单抗、奥英妥珠单抗和CD19 CAR T细胞治疗的MRD阴性完全缓解率分别为96.3%、60%和75%。
- 全部患者中位总生存为13.6个月(95% CI:9.6-17.2),不同挽救治疗间无显著差异(p=0.40)。
- 获得缓解后行异基因造血干细胞移植者12个月无白血病生存优于未移植者(35% vs 9%,p=0.014)。
核心结论
- 靶向与免疫治疗在携带TP53突变的成人B细胞急性淋巴细胞白血病中可有效诱导高MRD阴性缓解率,但无异基因造血干细胞移植巩固时缓解持续时间短,布林妥莫单抗后复发常表现为CD19阴性。
研究设计与样本
- 回顾性评估47例接受布林妥莫单抗、奥英妥珠单抗和/或CD19 CAR T细胞治疗的成人TP53突变急性淋巴细胞白血病患者的治疗结局。
主要发现
- 布林妥莫单抗(n=46)、奥英妥珠单抗(n=26)和CD19 CAR T细胞(n=6)治疗后的完全缓解伴或不伴血细胞计数恢复(CR/CRi)率分别为58.7%、61.5%和66.7%,MRD阴性率分别为96.3%、60%和75%。
- 全部患者中位总生存为13.6个月(95% CI:9.6-17.2),基于各新型挽救治疗间无显著差异(p=0.40)。
- 布林妥莫单抗、奥英妥珠单抗和CAR T细胞应答者的12个月无白血病生存分别为20%、11%和0%(p=0.743)。
- 获得缓解后行异基因造血干细胞移植者12个月无白血病生存优于未行者(35% vs 9%,p=0.014)。
- 布林妥莫单抗后复发患者中11例(61%)表现为CD19阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively evaluated the treatment outcomes of 47 adult patients with TP53-mutated acute lymphoblastic leukaemia (ALL) treated with either blinatumomab, inotuzumab or/and CD19 CAR T-cell therapy. The complete remission with or without count recovery (CR/CRi) (negative minimal residual disease (MRD-) rate) following treatment with blinatumomab (n = 46), inotuzumab (n = 26) and CD19 CAR T cells (n = 6) was 58.7% (96.3%), 61.5% (60%) and 66.7% (75%) respectively. The median OS was 13.6 months (95% CI: 9.6-17.2) for all patients, and it was not significantly different based on the individual novel salvage therapy (p = 0.40). The 12-month leukaemia-free survival (LFS) for responders to blinatumomab, InO and CAR T cells was 20%, 11% and 0% (p = 0.743) respectively. Patients who had undergone allogeneic haematopoietic stem cell transplantation (HSCT) post-response had improved 12-month LFS compared to those who did not (35% vs. 9%, p = 0.014). Among relapsed patients following blinatumomab, 11 (61%) presented with CD19-negative disease. Hence, targeted and immune-based therapies are effective in inducing high MRD-negative remission rates in adults with B-cell ALL harbouring TP53 mutations. Nonetheless, the durability of remission is short in the absence of allogeneic HCT consolidation and relapse frequently manifested as CD19-negative disease following blinatumomab.
引用
- Pourhassan H, Tinajero J, Ma H, et al. The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia. Br J Haematol. 2025. PMID: 40890465. doi:10.1111/bjh.20260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。